These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33157067)

  • 1. Important considerations for trials for peripheral arterial disease: Lessons learned from the paclitaxel mortality signal: A report on behalf of the registry assessment for peripheral interventional Devices (RAPID) Paclitaxel Pathways Program.
    Lottes AE; Whatley EM; Royce SM; Bertges DJ; Erickson CA; Farb A; Fox ML; Jiang JH; Wang L; Lin AY; Malone ML; Papandreou G; Wilgus RW; Rosenfield K; Krucoff MW
    Am Heart J; 2021 Feb; 232():71-83. PubMed ID: 33157067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mortality After Paclitaxel Coated Balloon Angioplasty and Stenting of Superficial Femoral and Popliteal Artery in the Vascular Quality Initiative.
    Bertges DJ; Sedrakyan A; Sun T; Eslami MH; Schermerhorn M; Goodney PP; Beck AW; Cronenwett JL; Eldrup-Jorgensen J
    Circ Cardiovasc Interv; 2020 Feb; 13(2):e008528. PubMed ID: 32069110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on paclitaxel for femoral-popliteal occlusive disease in the 15 months following a summary level meta-analysis demonstrated increased risk of late mortality and dose response to paclitaxel.
    Schneider PA; Varcoe RL; Secemsky E; Schermerhorn M; Holden A
    J Vasc Surg; 2021 Jan; 73(1):311-322. PubMed ID: 32890719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-coated balloons to improve femoropopliteal artery patency: Rationale and design of the LEVANT 2 trial.
    Jaff MR; Rosenfield K; Scheinert D; Rocha-Singh K; Benenati J; Nehler M; White CJ
    Am Heart J; 2015 Apr; 169(4):479-85. PubMed ID: 25819854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Comparison of Paclitaxel-Eluting Balloon and Stenting Versus Plain Balloon Plus Stenting Versus Directional Atherectomy for Femoral Artery Disease (ISAR-STATH).
    Ott I; Cassese S; Groha P; Steppich B; Hadamitzky M; Ibrahim T; Kufner S; Dewitz K; Hiendlmayer R; Laugwitz KL; Schunkert H; Kastrati A; Fusaro M
    Circulation; 2017 Jun; 135(23):2218-2226. PubMed ID: 28424222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel-coated peripheral artery devices are not associated with increased mortality.
    Kumins NH; King AH; Ambani RN; Thomas JP; Bose S; Shishehbor MH; Li J; Wong VL; Harth KC; Cho JS; Kashyap VS
    J Vasc Surg; 2020 Sep; 72(3):968-976. PubMed ID: 31917036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease.
    Ouriel K; Adelman MA; Rosenfield K; Scheinert D; Brodmann M; Peña C; Geraghty P; Lee A; White R; Clair DG
    JACC Cardiovasc Interv; 2019 Dec; 12(24):2515-2524. PubMed ID: 31575518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-year Review on Mortality and Morbidity after Femoropopliteal Drug-coated Balloon Angioplasty in the Randomized EffPac Trial.
    Teichgräber U; Lehmann T; Aschenbach R; Thieme M; Zeller T; Beschorner U; Scheinert D
    Radiology; 2020 Sep; 296(3):638-640. PubMed ID: 32692299
    [No Abstract]   [Full Text] [Related]  

  • 9. Paclitaxel-Coated Peripheral Arterial Devices are Associated with Reduced Mortality in Younger Patients.
    Kumins NH; King AH; Ambani RN; Thomas JP; Bose S; Wong VL; Harth KC; Cho JS; Colvard B; Kashyap VS
    Ann Vasc Surg; 2021 Jan; 70():70-78. PubMed ID: 32795647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Device Selection in Femoral-Popliteal Arterial Interventions.
    Kim SM; Kim LK; Feldman DN
    Interv Cardiol Clin; 2020 Apr; 9(2):197-206. PubMed ID: 32147120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-Dose Paclitaxel-Coated Versus Uncoated Percutaneous Transluminal Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease: One-Year Results of the ILLUMENATE European Randomized Clinical Trial (Randomized Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon).
    Schroeder H; Werner M; Meyer DR; Reimer P; Krüger K; Jaff MR; Brodmann M;
    Circulation; 2017 Jun; 135(23):2227-2236. PubMed ID: 28424223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: a meta-analysis of randomized trials.
    Cassese S; Byrne RA; Ott I; Ndrepepa G; Nerad M; Kastrati A; Fusaro M
    Circ Cardiovasc Interv; 2012 Aug; 5(4):582-9. PubMed ID: 22851526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality After Paclitaxel-Coated Device Use in Patients With Chronic Limb-Threatening Ischemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Dinh K; Gomes ML; Thomas SD; Paravastu SCV; Holden A; Schneider PA; Varcoe RL
    J Endovasc Ther; 2020 Apr; 27(2):175-185. PubMed ID: 32066315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel-Coated Balloons and Eluting Stents: Is There a Mortality Risk in Patients With Peripheral Artery Disease?
    Beckman JA; White CJ
    Circulation; 2019 Oct; 140(16):1342-1351. PubMed ID: 31177820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
    Kinstner CM; Lammer J; Willfort-Ehringer A; Matzek W; Gschwandtner M; Javor D; Funovics M; Schoder M; Koppensteiner R; Loewe C; Ristl R; Wolf F
    JACC Cardiovasc Interv; 2016 Jul; 9(13):1386-92. PubMed ID: 27388828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel and Mortality Following Peripheral Angioplasty: An Adjusted and Case Matched Multicentre Analysis.
    Saratzis A; Lea T; Yap T; Batchelder A; Thomson B; Saha P; Diamantopoulos A; Saratzis N; Davies R; Zayed H
    Eur J Vasc Endovasc Surg; 2020 Aug; 60(2):220-229. PubMed ID: 32370918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease.
    Mehrotra S; Paramasivam G; Mishra S
    Curr Cardiol Rep; 2017 Feb; 19(2):10. PubMed ID: 28185166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nationwide trends in drug-coated balloon and drug-eluting stent utilization in the femoropopliteal arteries.
    Mohapatra A; Saadeddin Z; Bertges DJ; Madigan MC; Al-Khoury GE; Makaroun MS; Eslami MH
    J Vasc Surg; 2020 Feb; 71(2):560-566. PubMed ID: 31405761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiographic and Clinical Outcomes After Treatment of Femoro-Popliteal Lesions with a Novel Paclitaxel-Matrix-Coated Balloon Catheter.
    Tepe G; Gögebakan Ö; Redlich U; Tautenhahn J; Ricke J; Halloul Z; Meyer DR; Waliszewski M; Schnorr B; Zeller T; Müller-Hülsbeck S; Ott I; Albrecht T
    Cardiovasc Intervent Radiol; 2017 Oct; 40(10):1535-1544. PubMed ID: 28660441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consensus minimum core data elements adapted to peripheral vascular intervention in the drug-eluting era: Consensus report from the Registry Assessment of Peripheral Interventional Devices (RAPID) Pathways "LEAN" working group.
    Black JH; Buckley D; Velezis M; Eldrup-Jorgensen J; Serratore ND; Gutierrez JA; Whatley E; Marmor RA; Bertges DJ; Tcheng JE; Royce S; Malone M; Farb A; Secemsky EA; Parikh SA; Smale J; Jaff MR; White R; Wilgus RW; Krucoff MW
    J Vasc Surg; 2023 Nov; 78(5):1313-1321. PubMed ID: 37524153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.